Vaccination route that induces transforming growth factor β production fails to elicit protective immunity against leishmania donovani infection ∇

Infection and Immunity

Volumn 77, Issue 4, 2009, Pages 1514-1523

  Bhowmick, Sudipta ^a   Mazumdar, Tuhina ^a,b   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; INTERLEUKIN 4; LIPOSOME; MEMBRANE ANTIGEN; NITRITE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; PARASITE ANTIGEN; PROTOZOAL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL KILLING; CELL PROTECTION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; ENCAPSULATION; HUMORAL IMMUNITY; INFECTION RESISTANCE; INTERFERON PRODUCTION; LEISHMANIA DONOVANI; LEISHMANIASIS; LIPOSOMAL DELIVERY; LIVER; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; TH1 CELL; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CULTURE; DRUG ADMINISTRATION ROUTE; IMMUNOLOGY; METHODOLOGY; PARASITOLOGY; PATHOGENICITY; PERITONEUM MACROPHAGE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIGENS, PROTOZOAN; CELLS, CULTURED; DRUG ADMINISTRATION ROUTES; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; VACCINATION;

EID: 63149142670     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01739-07     Document Type: Article

References (39)

1. Afrin, F., and N. Ali. 1997. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect. Immun. 65:2371-2377.
2. Afrin, F., and N. Ali. 1998. Isotype profiles of Leishmania donovani-infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigote antigens. J. Parasitol. 84:743-748.
3. Afrin, F., T. Dey, K. Anam, and N. Ali. 2001. Leishmanicidal activity of stearylamine-bearing liposomes in vitro. J. Parasitol. 87:188-193.
4. Barral-Netto, M., A. Barral, C. E. Brownell, Y. A. Skeiky, L. R. Ellingsworth, D. R. Twardzik, and S. G. Reed. 1992. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257:545-548.
5. Belkaid, Y. 2007. Regulatory T cells and infection: a dangerous necessity.Nat. Rev. Immunol. 7:875-888.
6. Belkaid, Y. 2008. Role of Foxp3-positive regulatory T cells during infection. Eur. J. Immunol. 38:918-921.
7. Bhowmick, S., R. Ravindran, and N. Ali. 2007. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 25:6544-6556.
8. Bogdan, C., and C. Nathan. 1993. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann. N. Y. Acad. Sci. 685:713-739.
9. Chen, Y., V. K. Kuchroo, J. Inobe, D. A. Hafler, and H. L. Weiner. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265:1237-1240.
10. Coffman, R. L., D. A. Lebman, and P. Rothman. 1993. Mechanism and regulation of immunoglobulin isotype switching. Adv. Immunol. 54:229-270.
11. Desjeux, P. 2004. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27:305-318.
12. Ding, A. H., C. F. Nathan, and D. J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407-2412.
13. Fonseca, S. G., P. R. Romao, F. Figueiredo, R. H. Morais, H. C. Lima, S. H. Ferreira, and F. Q. Cunha. 2003. TNF-alpha mediates the induction of nitric oxide synthase in macrophages but not in neutrophils in experimental cutaneous leishmaniasis. Eur. J. Immunol. 33:2297-2306.
14. Ghosh, A., W. W. Zhang, and G. Matlashewski. 2001. Immunization withA2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20:59-66.
15. Gorelik, L., and R. A. Flavell. 2002. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2:46-53.
16. Kedzierski, L., Y. Zhu, and E. Handman. 2006. Leishmania vaccines: progress and problems. Parasitology 133:S87-S112.
17. Liew, F. Y., C. Hale, and J. G. Howard. 1985. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J. Immunol. 135:2095-2101.
18. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
19. Mazumdar, T., K. Anam, and N. Ali. 2004. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22:1162-1171.
20. McMahon-Pratt, D., and J. Alexander. 2004. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol. Rev. 201:206-224.
21. Meade, R., P. W. Askenase, G. P. Geba, K. Neddermann, R. O. Jacoby, and R. D. Pasternak. 1992. Transforming growth factor-beta 1 inhibits murine immediate and delayed type hypersensitivity. J. Immunol. 149:521-528.
22. Mendez, S., Y. Belkaid, R. A. Seder, and D. Sacks. 2002. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702-3708.
23. Mills,K.H.2004. RegulatoryTcells: friendorfoeinimmunitytoinfection? Nat. Rev. Immunol. 4:841-855.
24. Mukhopadhyay, S., S. Bhattacharyya, R. Majhi, T. De, K. Naskar, S. Ma- jumdar, and S. Roy. 2000. Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 7:233-240.
25. Murray, H. W., and C. F. Nathan. 1999. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189:741-746.
26. Murray, H. W., C. M. Lu, S. Mauze, S. Freeman, A. L. Moreira, G. Kaplan, and R. L. Coffman. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70:6284-6293.
27. H1 cells control themselves by producing interleukin-10. Nat. Rev. Immunol. 7:425-428.
28. Prud'homme, G. J., and C. A. Piccirillo. 2000. The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J. Autoimmun. 14:23-42.
29. Rosas, L. E., H. M. Snider, J. Barbi, A. A. Satoskar, G. Lugo-Villarino, T. Keiser, T. Papenfuss, J. E. Durbin, D. Radzioch, L. H. Glimcher, and A. R. Satoskar. 2006. Cutting edge: STAT1 and T-bet play distinct roles in deter-mining outcome of visceral leishmaniasis caused by Leishmania donovani. J. Immunol. 177:22-25.
30. Saha, S., S. Mondal, R. Ravindran, S. Bhowmick, D. Modak, S. Mallick, M. Rahman, S. Kar, R. Goswami, S. K. Guha, N. Pramanik, B. Saha, and N. Ali. 2007. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post- kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J. Immunol. 179:5592-5603.
31. Stager, S., D. F. Smith, and P. M. Kaye. 2000. Immunization with a recom- binant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165:7064-7071.
32. Stauber, L. A., E. M. Franchino, and J. Grun. 1958. An 8-day method for screening compounds against Leishmania donovani in the golden hamster. J. Protozool. 5:269-273.
33. Tabbara, K. S., N. C. Peters, F. Afrin, S. Mendez, S. Bertholet, Y. Belkaid, and D. L. Sacks. 2005. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect. Immun. 73:4714-4722.
34. Vodovotz, Y., C. Bogdan, J. Paik, Q. W. Xie, and C. Nathan. 1993. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J. Exp. Med. 178:605-613.
35. Wei, X. Q., I. G. Charles, A. Smith, J. Ure, G. J. Feng, F. P. Huang, D. Xu, W. Muller, S. Moncada, and F. Y. Liew. 1995. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375:408-411.
36. Weiner, H. L. 2001. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect. 3:947-954.
37. Wijburg, O. L., G. P. van den Dobbelsteen, J. Vadolas, A. Sanders, R. A. Strugnell, and N. van Rooijen. 1998 The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur. J. Immunol. 28:479-487.
38. Williams, M. E., P. Caspar, I. Oswald, H. K. Sharma, O. Pankewycz, A. Sher, and S. L. James. 1995. Vaccination routes that fail to elicit protective immunity against Schistosoma mansoni induce the production of TGF-beta, which down-regulates macrophage antiparasitic activity. J. Immunol. 154:4693-4700.
39. Wilson, M. E., S. M. Jeronimo, and R. D. Pearson. 2005. Immunopathogen- esis of infection with the visceralizing Leishmania species. Microb. Pathog. 38:147-160.